Key result
Intravenous administration of DNAzymes targeting Egr-1 attenuated pulmonary vascular remodelling and the development of occlusive neointimal lesions in rats with experimental flow-associated PAH.
Why the study?
Does Egr-1 down-regulation attenuate pulmonary vascular remodelling in experimental flow-associated PAH in rats?
Does Egr-1 down-regulation attenuate pulmonary vascular remodelling in experimental flow-associated PAH in rats?
Down-regulation of Egr-1 attenuates pulmonary vascular remodeling and right ventricular hypertrophy in experimental flow-associated PAH, suggesting Egr-1 as a potential therapeutic target.
Answers are grounded in this paper and cite their sources.
Egr-1 targeting merits exploration in PAH; hypothesis-generating in animal models and should not yet change practice.
AIMS: Pulmonary arterial hypertension (PAH) is characterized by the development of unique neointimal lesions in the small pulmonary arteries, leading to increased right ventricular (RV) afterload and failure. Novel therapeutic strategies are needed that target these neointimal lesions. Recently, the transcription factor Egr-1 (early growth response protein 1) was demonstrated to be up-regulated early in experimental neointimal PAH. Its effect on disease development, however, is unknown. We aimed to uncover a novel role for Egr-1 as a molecular inductor for disease development in PAH. METHODS AND RESULTS: In experimental flow-associated PAH in rats, we investigated the effects of Egr-1 down-regulation on pulmonary vascular remodelling, including neointimal development, and disease progression. Intravenous administration of catalytic oligodeoxynucleotides (DNA enzymes, DNAzymes) resulted in down-regulation of pulmonary vascular Egr-1 expression. Compared with vehicle or scrambled DNAzymes, DNAzymes attenuated pulmonary vascular remodelling, including the development of occlusive neointimal lesions. Selective down-regulation of Egr-1 in vivo led to reduced expression of vascular PDGF-B, TGF-β, IL-6, and p53, resulting in a reduction of vascular proliferation and increased apoptosis. DNAzyme treatment further attenuated pulmonary vascular resistance, RV systolic pressure, and RV hypertrophy. In contrast, in non-neointimal PH rodents, DNAzyme treatment had no effect on pulmonary vascular and RV remodelling. Finally, pharmacological inhibition of Egr-1 with pioglitazone, a peroxisome proliferator activated receptor-γ ligand, attenuated vascular remodelling including the development of neointimal lesions. CONCLUSIONS: These results indicate that Egr-1 governs pulmonary vascular remodelling and the development of characteristic vascular neointimal lesions in flow-associated PAH. Egr-1 is therefore a potential target for future PAH treatment.
No takes yet. Share an insight, caveat, or question.
Dickinson et al. (2014) studied Pulmonary arterial hypertension (PAH). Catalytic oligodeoxynucleotides (DNAzymes) targeting Egr-1 vs. Vehicle or scrambled DNAzymes was evaluated on Pulmonary vascular remodelling and neointimal development. Intravenous administration of DNAzymes targeting Egr-1 attenuated pulmonary vascular remodelling and the development of occlusive neointimal lesions in rats with experimental flow-associated PAH.
Synapse has enriched 10 related papers. Consider them for comparative context: